CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

Cun WangHui WangCor LieftinkAimee du ChatinierDongmei GaoGuangzhi JinHaojie JinRoderick L BeijersbergenWenxin QinRené Bernards

Published in: Gut (2019)

Our data highlight the potential of CDK12 as a drug target for patients with HCC. The striking synergy of THZ531 and sorafenib suggests a potential combination therapy for this difficult to treat cancer.

Keyphrases

dna damage
cell cycle
papillary thyroid
oxidative stress
human health
squamous cell
dna repair
squamous cell carcinoma
emergency department
risk assessment
machine learning
cell proliferation
climate change
deep learning